CHEMOTHERAPY AND G-CSF PRIMED PERIPHERAL-BLOOD CD34 POSITIVE STEM-CELLS WHICH PROVIDE HEMATOPOIETIC RECONSTITUTION AFTER HIGH-DOSE CHEMOTHERAPY CONTAIN A SUBSET OF HLA-DR NEGATIVE, CD38 NEGATIVE CELLS

被引：0

作者：

MAHARAJ, D ^{[1
]}

RILEY, R ^{[1
]}

ONEILL, GJ ^{[1
]}

PHILLIPS, J ^{[1
]}

ELIA, J ^{[1
]}

机构：

[1] UNIV MIAMI,SCH MED,DEPT MICROBIOL IMMUNOL,DIV HEMATOL ONCOL,BONE MARROW TRANSPLANT PROGRAM,MIAMI,FL 33152

来源：

BLOOD | 1993年 / 82卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A13 / A13

页数：1

共 50 条

[31] PHASE-II STUDY OF AUTOLOGOUS FILGRASTIM (G-CSF)-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO RESTORE HEMATOPOIESIS AFTER HIGH-DOSE CHEMOTHERAPY FOR LYMPHOID MALIGNANCIES [J].

SHERIDAN, WP ;

BEGLEY, CG ;

TO, LB ;

GRIGG, A ;

SZER, J ;

MAHER, D ;

GREEN, MD ;

ROWLINGS, PA ;

MCGRATH, KM ;

CEBON, J ;

DYSON, P ;

WATSON, D ;

BAYLY, J ;

DELUCA, E ;

TOMITA, D ;

HOFFMAN, E ;

MORSTYN, G ;

JUTTNER, CA ;

FOX, RM .

BONE MARROW TRANSPLANTATION, 1994, 14 (01) :105-111

[32] INTENSIVE CHEMOTHERAPY AND G-CSF ARE CAPABLE IN CML PATIENTS OF RECRUITING CD34+/DR- CELLS WITH HIGH PROLIFERATIVE POTENTIAL AND SUSTAIN PH-NEGATIVE POLYCLONAL HEMATOPOIESIS [J].

CARELLA, AM ;

FRASSONI, F ;

PODESTA, M ;

POLLICARDO, N ;

PUNGOLINO, E ;

RAFFO, MR ;

FERRERO, R ;

BERGAMASCHI, G ;

ROSTI, V ;

CAZZOLA, M ;

SAGLIO, G .

BLOOD, 1993, 82 (10) :A297-A297

[33] Analysis of expression of CD 38, CD 71 and HLA DR (maturity markers), c-kit receptor and adhesion molecules on CD 34+ peripheral blood cells after mobilization with G-CSF and/or cytotoxic drugs. [J].

Nasilowska, B ;

Wozniak, J ;

Kopec-Szlezak, J ;

Marianska, B ;

Szczepinski, A ;

Podstawka, U ;

Antoniewicz-Papis, J ;

Rzepecki, P .

BLOOD, 2003, 102 (11) :144B-144B

[34] Ex-vivo generation of granulopoietic post-progenitor cells from mobilized peripheral blood CD34(+) cells for clinical use after high-dose chemotherapy and peripheral blood progenitor transplantation. [J].

Scheding, S ;

Brugger, W ;

Buhring, HJ ;

Ziegler, B ;

Bock, T ;

Kanz, L .

EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) :116-116

[35] CD34 CONTENT OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IS THE SINGLE MOST POWERFUL PREDICTOR OF RECOVERY KINETICS IN PATIENTS RECEIVING MYELOABLATIVE HIGH-DOSE CHEMOTHERAPY (HDC) AND PBPC INFUSION [J].

WEAVER, CH ;

BIRCH, R ;

SCHWARTZBERG, L ;

PALMER, P ;

WEST, W ;

HAZELTON, B .

BLOOD, 1994, 84 (10) :A351-A351

[36] RAPID PLATELET RECOVERY-TIME FOLLOWING HIGH-DOSE CHEMOTHERAPY (HDT) FOR METASTATIC BREAST-CANCER SUPPORTED BY HEMATOPOIETIC STEM-CELLS COLLECTED FROM BLOOD (BSC) AFTER G-CSF ADMINISTRATION [J].

GEILS, GF ;

TILDEN, AB ;

CARABASI, MH ;

FRIEDBERG, RC ;

VAUGHAN, WP .

BLOOD, 1994, 84 (10) :A709-A709

[37] Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial [J].

Stewart, AK ;

Vescio, R ;

Schiller, G ;

Ballester, O ;

Noga, S ;

Rugo, H ;

Freytes, C ;

Stadtmauer, E ;

Tarantolo, S ;

Sahebi, F ;

Stiff, P ;

Meharchard, J ;

Schlossman, R ;

Brown, R ;

Tully, H ;

Benyunes, M ;

Jacobs, C ;

Berenson, R ;

White, M ;

DiPersio, J ;

Anderson, KC ;

Berenson, J .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) :3771-3779

[38] Short- and long-term safety of the 2 x 106 CD34+cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support [J].

Corsini, C ;

Bertolini, F ;

Mancuso, P ;

Cinieri, S ;

Peccatori, F ;

Martinelli, G .

ANNALS OF ONCOLOGY, 2002, 13 (06) :983-985

[39] Chemotherapy/G-CSF mobilization and a single large volume leukapheresis (LVL) can yield greater than 1X10(7) CD34(+) peripheral blood stem cells/KG [J].

Maharaj, D ;

Avner, BP ;

Southwick, LJ ;

Bowe, SD ;

Gouvea, JV ;

Phillips, J ;

ONeill, JG .

BLOOD, 1995, 86 (10) :3939-3939

[40] THE PEAK NUMBERS OF COLONY-FORMING CELLS AND OF CD34+ CELLS RELEASED INTO PERIPHERAL-BLOOD AFTER G-CSF (LENOGRASTIM) WITH OR WITHOUT CHEMOTHERAPY MAY NOT BE CORRELATED WITH THE CAPACITY OF HARVESTED BLOOD-CELLS TO REPOPULATE BONE-MARROW [J].

BAUMANN, I ;

VANHOEF, MEHM ;

SWINDELL, R ;

LANGE, C ;

DEWYNTER, E ;

HOWELL, A ;

DEXTER, TM ;

TESTA, NG .

EXPERIMENTAL HEMATOLOGY, 1994, 22 (08) :765-765

← 1 2 3 4 5 →